Eric B Elbogen1,2, Amber Alsobrooks2, Sara Battles2, Kiera Molloy2, Paul A Dennis1,2, Jean C Beckham1,2, Samuel A McLean3, Julian R Keith4, Carmen Russoniello5. 1. Veterans Affairs (VA) Mid-Atlantic Mental Illness Research, Education and Clinical Center (MIRECC), Durham, North Carolina, USA. 2. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA. 3. Department of Anesthesiology, University of North Carolina-Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA. 4. Department of Psychology, University of North Carolina-Wilmington, Wilmington, North Carolina, USA. 5. Center for Applied Psychophysiology, East Carolina University, Greenville, North Carolina, USA.
Abstract
OBJECTIVE: Chronic pain is common in military veterans with traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). Neurofeedback, or electroencephalograph (EEG) biofeedback, has been associated with lower pain but requires frequent travel to a clinic. The current study examined feasibility and explored effectiveness of neurofeedback delivered with a portable EEG headset linked to an application on a mobile device. DESIGN: Open-label, single-arm clinical trial. SETTING: Home, outside of clinic. SUBJECTS: N = 41 veterans with chronic pain, TBI, and PTSD. METHOD: Veterans were instructed to perform "mobile neurofeedback" on their own for three months. Clinical research staff conducted two home visits and two phone calls to provide technical assistance and troubleshoot difficulties. RESULTS: N = 36 veterans returned for follow-up at three months (88% retention). During this time, subjects completed a mean of 33.09 neurofeedback sessions (10 minutes each). Analyses revealed that veterans reported lower pain intensity, pain interference, depression, PTSD symptoms, anger, sleep disturbance, and suicidal ideation after the three-month intervention compared with baseline. Comparing pain ratings before and after individual neurofeedback sessions, veterans reported reduced pain intensity 67% of the time immediately following mobile neurofeedback. There were no serious adverse events reported. CONCLUSIONS: This preliminary study found that veterans with chronic pain, TBI, and PTSD were able to use neurofeedback with mobile devices independently after modest training and support. While a double-blind randomized controlled trial is needed for confirmation, the results show promise of a portable, technology-based neuromodulatory approach for pain management with minimal side effects. 2019 American Academy of Pain Medicine.
OBJECTIVE: Chronic pain is common in military veterans with traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). Neurofeedback, or electroencephalograph (EEG) biofeedback, has been associated with lower pain but requires frequent travel to a clinic. The current study examined feasibility and explored effectiveness of neurofeedback delivered with a portable EEG headset linked to an application on a mobile device. DESIGN: Open-label, single-arm clinical trial. SETTING: Home, outside of clinic. SUBJECTS: N = 41 veterans with chronic pain, TBI, and PTSD. METHOD: Veterans were instructed to perform "mobile neurofeedback" on their own for three months. Clinical research staff conducted two home visits and two phone calls to provide technical assistance and troubleshoot difficulties. RESULTS: N = 36 veterans returned for follow-up at three months (88% retention). During this time, subjects completed a mean of 33.09 neurofeedback sessions (10 minutes each). Analyses revealed that veterans reported lower pain intensity, pain interference, depression, PTSD symptoms, anger, sleep disturbance, and suicidal ideation after the three-month intervention compared with baseline. Comparing pain ratings before and after individual neurofeedback sessions, veterans reported reduced pain intensity 67% of the time immediately following mobile neurofeedback. There were no serious adverse events reported. CONCLUSIONS: This preliminary study found that veterans with chronic pain, TBI, and PTSD were able to use neurofeedback with mobile devices independently after modest training and support. While a double-blind randomized controlled trial is needed for confirmation, the results show promise of a portable, technology-based neuromodulatory approach for pain management with minimal side effects. 2019 American Academy of Pain Medicine.
Authors: Arkadiusz Stopczynski; Carsten Stahlhut; Michael Kai Petersen; Jakob Eg Larsen; Camilla Falk Jensen; Marieta Georgieva Ivanova; Tobias S Andersen; Lars Kai Hansen Journal: Int J Psychophysiol Date: 2013-08-29 Impact factor: 2.997
Authors: Shannon M Blakey; H Ryan Wagner; Jennifer Naylor; Mira Brancu; Ilana Lane; Meghann Sallee; Nathan A Kimbrel; Eric B Elbogen Journal: J Pain Date: 2018-03-08 Impact factor: 5.820
Authors: Mark P Jensen; Kevin J Gertz; Amy E Kupper; Alan L Braden; Jon D Howe; Shahin Hakimian; Leslie H Sherlin Journal: Appl Psychophysiol Biofeedback Date: 2013-06
Authors: Diana M Higgins; Robert D Kerns; Cynthia A Brandt; Sally G Haskell; Harini Bathulapalli; Wesley Gilliam; Joseph L Goulet Journal: Pain Med Date: 2014-02-18 Impact factor: 3.750
Authors: Chester C Buckenmaier; Kevin T Galloway; Rosemary C Polomano; Mary McDuffie; Nancy Kwon; Rollin M Gallagher Journal: Pain Med Date: 2012-11-08 Impact factor: 3.750
Authors: Jeffrey M Rogers; Stuart J Johnstone; Anna Aminov; James Donnelly; Peter H Wilson Journal: Int J Psychophysiol Date: 2016-06-16 Impact factor: 2.997
Authors: Héctor Rieiro; Carolina Diaz-Piedra; José Miguel Morales; Andrés Catena; Samuel Romero; Joaquin Roca-Gonzalez; Luis J Fuentes; Leandro L Di Stasi Journal: Sensors (Basel) Date: 2019-06-23 Impact factor: 3.576
Authors: Beth E Cohen; Kris Gima; Daniel Bertenthal; Sue Kim; Charles R Marmar; Karen H Seal Journal: J Gen Intern Med Date: 2009-09-29 Impact factor: 5.128
Authors: Kajal Patel; James Henshaw; Heather Sutherland; Jason R Taylor; Alexander J Casson; Karen Lopez-Diaz; Christopher A Brown; Anthony K P Jones; Manoj Sivan; Nelson J Trujillo-Barreto Journal: Front Neurosci Date: 2021-02-22 Impact factor: 4.677